



2020 EMERGING THERAPIES FOR PBC, NASH, ESLD AND HCC SEMINAR SERIES

Ft. Lauderdale, FL May 30, 2020

Conference	Sheraton Suites Fort Lauderdale at	Phone: (954) 772-5400	
Location	Cypress Creek 555 NW 62nd St	https://www.marriott.com/hotels/travel/fllsc-sheraton-suites-fort-lauderdale-at-cypress-creek/	
	Fort Lauderdale, Florida		
Parking at the Conference	Complimentary self-parking rate has been arranged for program participants		
Driving Directions	 From the Ft Lauderdale Airport Follow I-95 N toward West Follow I-95 N to NE 62nd St/E Cypress Creek Rd in Oakland Park. Take exit 33B from I-95 N, Merge onto I-95 N, Take exit 33B toward West Cypress Creek Follow NE 62nd St/E Cypress Creek Rd to your destination in Fort Lauderdale, Merge onto NE 62nd St/E Cypress Creek Rd, Turn right, Sheraton Suites Fort Lauderdale at Cypress Creek. 		
Seminar Agenda and Syllabus Information	Registration and breakfast begin at 7:30 a.m. in Grand Salon I. Please check signage for any last minute room changes. The Emerging Therapies seminar is a paperless program. The course syllabus and related materials will be made available on a digital app that can be accessed by a smart phone, tablet device or personal computer. Instructions to download the <i>App</i> will be provided to participants in advance of the seminar. WiFi will be available without charge.		
7:30 am	Registration, Continental Breakfast & View Exhibits		
8:00 am	Opening Comments and Pre-Test		
8:20 am	 End Stage Liver Disease: Treatment, Managing Complications and Transplant Staging, workup, and diagnosis of cirrhosis Medical care of the patient with end stage liver disease Liver Transplantation Listing criteria, MELD scores, Exceptions and the transplant process Case Study 1 – Cirrhosis and Encephalopathy 		
9:25 am	Hepatocellular Carcinoma (HCC)		
10:00 am	Break & View Exhibits		
10:15 am	 Hepatocellular Carcinoma: New Systemic Treatment Options Current FDA-Approved Therapies New chemotherapy regimens in development and testing Immunotherapy as the new MoA for HCC Case Study 2 – Diagnosis and Treatment of Hepatocellular Carcinoma 		
11:00 am	Primary Sclerosing Cholangitis (PSC) and Primary Biliary Cholangitis • Epidemiology of PSC and Ursodiol and Antibiotic Treatments • Predicting outcomes and Improving Survival in PSC patients		

	Causes and Markers of PBC	
	Ursodeoxycholic Acid (UDCA) and Obeticholic Acid	
11:40 am	Hepatology Update I – Viral Hepatitis	
	• The reemergence of Hepatitis A, Autoimmune Hepatitis and Transplanting HCV+ organs	
12:15 pm	Luncheon Presentation	
12:55pm	Dessert and View Exhibits	
1:10pm	Hepatology Update II Emerging Topics in Liver Disease	
	Alcoholic Liver Disease, Liver disease and Pregnancy, Hepatorenal syndrome	
	NAFLD, LAL-D and NASH	
	 Epidemiology, Demographics and Diagnosis 	
1:40 pm	• Treatment options for thrombocytopenia; including alternatives to platelet transfusion.	
	Treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D) causing adult	
	Fatty Liver Disease	
2:15 pm	Break & View Exhibits	
	NASH Treatments in Practice and in Development	
	Current therapies for NASH	
2:30 pm	Life style changes as a therapy	
	Drugs in clinical development for NASH	
	Case Study 3 - NASH Diagnosis and Treatment	
3:30 pm	Post-test and Wrap-Up	

Attendee Cancellation, Substitution, Refund

The course tuition is refundable, minus a \$20 processing fee, if your cancellation is **received in writing no later than seven days prior** to the conference. Attendee substitutions are allowed, but notification must be made in writing seven days prior to the conference. After that date, no refunds, credits, or substitutions will be granted. No refunds or credits will be given to those who "no show."

Recording and Photography

The University of Louisville reserves exclusive rights to record (audio and video) and/or photograph conference proceedings for use in marketing materials, future presentations and other purposes.

Attendance Policies

Guest Attendance

All conference activities (including educational sessions, meal functions, exhibit hall participation and others) are exclusively reserved for seminar participants. Non-registered guests (including children, family members, colleagues and others.) are not permitted in the seminar areas.

Conference Modification or Cancellation

The University of Louisville and SC Liver Research Consortium reserve the right to modify the course's schedule, faculty or content if necessary. They also reserve the right to cancel this seminar, and in the unlikely event, a full refund of the registration fee will be provided. We are unable to refund any travel costs (flight, hotel, etc.) in the case of a seminar cancellation.

Physicians (MD/DO) - The University of Louisville Office of Continuing Medical Education & Professional Development designates this live activity for a maximum of **6.0** *AMA PRA Category 1 Credit(s)*TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Information

Nurses - This program has been approved by the Kentucky Board of Nursing for 7.3 continuing education credits through University of Louisville Hospital, provider number 4-0068-7-20-1150. The Kentucky Board of Nursing approval of an individual nursing education provide does not constitute endorsement of program content.

Nurse Practitioners and Physician Assistants - AANP and AAPA accept Category I credit from AMA PRA Category 1 Credit(s)TM organizations accredited by ACCME.

PAUL MARTIN, MD



Paul Martin is Professor of Medicine and Chief of the Divisions of Gastroenterology and Hepatology at the University of Miami, Miami, USA. He is a native of Dublin, Ireland, where he graduated with honors from medical school at University College, Dublin. He received a Doctorate in Medicine from the National University of Ireland. Dr. Martin specializes in internal medicine and gastroenterology, training initially in Dublin and subsequently in Canada. He trained in hepatology as a Fellow in the Liver Unit at the National Institutes of Health in Maryland. He is Editor-in Chief of *Liver Transplantation* and Chair of the Gastroenterology Board at ABIM where he serves on the Council. He was previously a Councilor at Large on the Board of the American Society of Transplant. He is a Fellow of the Royal Colleges of Physicians of Ireland and London. He has had a long standing interest in viral hepatitis and organ transplant.

ROBERTO FIRPI-MORELL, MD



Your Seminar Faculty Dr. Roberto J. Firpi is an Associate Professor of Medicine at the University of Florida's Division of Gastroenterology where he serves as the program director of the Transplant Hepatology Fellowship Program for the Section of Hepatobiliary Diseases and Liver Transplantation. He received his medical degree from the University of Puerto Rico School Of Medicine in 1994, completed a residency in internal medicine at the University of Puerto Rico where he also served as Chief Resident, and obtained fellowship training in gastroenterology and hepatology at the University of Florida additional training in hepatology and liver transplantation at Cedars Sinai Medical Center in Los Angeles, CA, where he received the AASLD Advanced Hepatology Fellowship Award. Dr. Firpi's area of clinical expertise is hepatology with an emphasis on the management of liver transplantation, viral hepatitis, fatty liver and immunosuppression after liver transplantation. Dr. Firpi has strong clinical and translational research interests and has published multiple papers in the area of hepatitis C and liver transplant and has become a leader in the area.

CARLA MOLLINER, MMS, PA-C



Carla Molliner is a nationally certified physician assistant specializing in hepatology at the University of Miami, Hepatology division. She graduated and completed PA school from Miami-Dade College in 2004 then earned her Master of Medical Science degree at Nova Southeastern University. She holds the national board recertification examination by the National Commission for Certification of Physician Assistants. Carla was awarded an NP/PA clinical Hepatology fellowship from the American Association for the Study of Liver Disease (AASLD) between 2005 and 2006. Followed by joining the University of Miami in the outpatient Hepatology clinic. She then joined the inpatient hepatology consult team, and has been an integral member for the past three years. She was recognized as a "U"-Shine employee for continuously exhibiting teamwork, professional manner, and excellent patient care among other distinguished behaviors.